###begin article-title 0
The proteoglycan osteoglycin/mimecan is correlated with arteriogenesis
###end article-title 0
###begin p 1
###xml 178 184 <span type="species:ncbi:9986">rabbit</span>
###xml 230 236 <span type="species:ncbi:9986">rabbit</span>
Arteriogenesis or collateral growth is able to compensate for the stenosis of major arteries. Using differential display RT-PCR on growing and quiescent collateral arteries in a rabbit femoral artery ligation model, we cloned the rabbit full-length cDNA of osteoglycin/mimecan. Osteoglycin was present in the adventitia of collateral arteries as a glycosylated protein without keratan sulfate side chains, mainly produced by smooth muscle cells (SMCs) and perivascular fibroblasts. Northern blot, Western blot, and immunohistochemistry confirmed a collateral artery-specific downregulation of osteoglycin from 6 h to 3 weeks after the onset of arteriogenesis. Treatment of primary SMCs with the arteriogenic protein fibroblast growth factor-2 (FGF-2) resulted in a similar reduction of osteoglycin expression as observed in vivo. Application of the FGF-2 inhibitor polyanethole sulfonic acid (PAS) blocked the downregulation of osteoglycin and interfered with arteriogenesis. From our study we conclude that downregulation of osteoglycin is a fundamental requirement for proper arteriogenesis.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 90 91 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 724 725 724 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 785 786 785 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 788 789 788 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 1132 1133 1132 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1458 1459 1458 1459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 1461 1462 1461 1462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1629 1630 1629 1630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 1669 1670 1669 1670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 331 336 <span type="species:ncbi:9606">human</span>
###xml 1338 1344 <span type="species:ncbi:9986">rabbit</span>
###xml 1590 1594 <span type="species:ncbi:7962">Carp</span>
Diseases of the cardio-vascular system are the main cause of death in the USA and Europe [1]. Often these problems arise from the occlusion of a main artery, leading to a decrease in blood supply in areas distal to the occlusion. If the stenosis of a large feeding artery proceeds sufficiently slow (e.g., in weeks or months), the human body is able to compensate for the effects of these occlusions, the most effective mechanism of which is the growth of collateral arteries (arteriogenesis) [2]. These collateral arteries develop from preexisting anastomoses creating a natural bypass bridging the occluded artery. The main stimulus for arteriogenesis is shear stress in contrast to angiogenesis which relies on ischemia [3]. In fact, collateral growth is not dependent on ischemia [4, 5]. Arteriogenesis is a complex process, which starts with a structural dilatation of the collateral artery wall, followed by a well-orchestrated mechanism of vascular growth. This requires endothelial activation, leukocyte recruitment, cell proliferation, cell death, smooth muscle cell (SMC) phenotypic shift, and vascular matrix remodeling [6]. The whole process is triggered by various growth factors and cytokines, e.g., monocyte chemoattractant protein (MCP-1) or fibroblast growth factor-2 (FGF-2). These factors stimulate arteriogenesis in a rabbit model, leading to a faster compensation of the blood flow deficit caused by the occlusion of the femoral artery [7, 8]. In addition, genes which are involved in the regulation of the cytoskeleton or the extracellular matrix (ECM) or others like Carp (cardiac ankyrin repeat protein) [9] and urokinase plasminogen activator [4] are differentially expressed during arteriogenesis.
###end p 4
###begin p 5
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 127 133 <span type="species:ncbi:9986">rabbit</span>
In order to identify additional genes involved in collateral growth, we started a screen for differentially expressed genes in rabbit collateral arteries after 3 days and 3 weeks of ligation of the femoral artery using differential display reverse transcription-polymerase chain reaction (DDRT-PCR) [10].
###end p 5
###begin p 6
###xml 53 54 53 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="Fn1">1</xref>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1017 1018 1017 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1178 1179 1178 1179 <bold xmlns:xlink="http://www.w3.org/1999/xlink">,</bold>
###xml 36 42 <span type="species:ncbi:9986">rabbit</span>
###xml 58 63 <span type="species:ncbi:9606">human</span>
###xml 526 532 <span type="species:ncbi:9986">rabbit</span>
###xml 592 598 <span type="species:ncbi:9986">rabbit</span>
###xml 1276 1282 <span type="species:ncbi:9986">rabbit</span>
One of the genes identified was the rabbit orthologue1 of human osteoinductive factor/osteoglycin [11] or mimecan [12]. Osteoglycin belongs to the family of small leucine-rich proteoglycans, a group of currently 11 proteins, characterized by leucine-rich repeats in their central domain. These proteins are located in the ECM and are important for the regulation of the structure of the matrix, but also in the regulation of cell cycle and growth factor actions [13-15]. Here, we present an in depth study on osteoglycin in a rabbit model of arteriogenesis. We cloned the full-length cDNA of rabbit osteoglycin and investigated its expression on RNA and protein level in growing collateral arteries, in a time course of 3 weeks starting with the induction of arteriogenesis by femoral artery ligation. The distribution of osteoglycin mRNA and protein was explored by in situ hybridization and immunohistochemistry, respectively. To define the modification status of the protein, we performed Western blot analysis on N-glycanase treated osteoglycin. In addition, we carried out several in vitro studies using factors known to stimulate either arteriogenesis or SMC proliferation, aiming to characterize their potential to regulate osteoglycin expression. Finally, we used the rabbit femoral ligation model to test the capacity of one of these factors (FGF-2) to regulate osteoglycin expression in vivo and to confirm the relevance of this proteoglycan in the arteriogenic process.
###end p 6
###begin title 7
Material and methods
###end title 7
###begin title 8
Animal model
###end title 8
###begin p 9
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 99 106 <span type="species:ncbi:9986">rabbits</span>
###xml 143 150 <span type="species:ncbi:9986">rabbits</span>
To induce collateral artery growth, we used the femoral artery ligation model in New Zealand White rabbits as described before [16]. In brief, rabbits were anesthetized with a ketamine/xylacine mixture and the right femoral artery was occluded with two ligatures 1.5 cm apart from each other. As a control the left femoral artery was sham operated. Animal care and all experimental procedures were performed in accordance to the German and National Institutes of Health animal legislation guidelines and were approved by the local animal care and use committees.
###end p 9
###begin p 10
###xml 453 455 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
For gene expression studies on RNA and protein level, collateral arteries were isolated 3, 6, 12, 24 h, 3, 7 days, and 3 weeks after occlusion of the femoral artery or after sham operation. All samples were snap frozen in liquid nitrogen or embedded in Tissue-teck mounting media (Sakura Finitek, Heppenheim, Germany) and stored at -80degreesC until further analyses. Postmortem angiograms of the whole hind limb were performed as previously described [16].
###end p 10
###begin title 11
Infusion of PAS
###end title 11
###begin p 12
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 207 208 205 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 153 160 <span type="species:ncbi:9986">rabbits</span>
###xml 424 431 <span type="species:ncbi:9986">rabbits</span>
The experimental treatment and the surgical procedure were performed as previously described [17]. In brief, after ligation of the right femoral artery, rabbits (body weight 3.7 +/- 0.5 kg, aged 3-4 months; n = 4) received polyanethole sulfonic acid (PAS) (15 mg/kg per day, Peprotech, Frankfurt, Germany), via an osmotic minipump connected to the collateral circulation. All animals tolerated the treatment well. At day 7, rabbits were subjected to angiography, and collateral arteries from the occluded and the control legs were isolated and snap frozen as described above.
###end p 12
###begin title 13
RNA isolation, DDRT-PCR, and Northern blot
###end title 13
###begin p 14
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 1018 1019 1017 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
Isolation of total RNA, DDRT-PCR, and Northern blot were performed according to standard procedures [18-20]. Differentially expressed cDNAs were cloned in pGEM-T Easy vector (Promega, Mannheim, Germany) or in pCR-Script Amp SK(+) (Stratagene, La Jolla, USA) and sequenced. Full-length osteoglycin cDNA was obtained by 5' RACE using a SMART RACE cDNA amplification kit (Clontech, Mountain View, USA). For Northern hybridization, 15 mug total RNA from growing and quiescent collateral arteries were separated on a 1% agarose gel containing 0.66 M formaldehyde and transferred to Nylon membrane (Duralon UV-membrane, Stratagene, La Jolla, USA). The blots were hybridized with [32P] dCTP random-primed labeled cDNA probes (Rediprime II, Amersham Biosciences, Freiburg, Germany), exposed to Storage phosphor screens overnight, and scanned using a Storm 860 PhosphorImager (Amersham Biosciences, Freiburg, Germany). For normalization, blots were rehybridized with a specific 18S RNA oligonucleotide as described previously [4]. Quantification of the signals was done using ImageQuant software (Amersham Biosciences, Feiburg, Germany). All experiments were repeated three times independently.
###end p 14
###begin title 15
Antibodies and Western blot analyses
###end title 15
###begin p 16
###xml 416 417 416 417 <bold xmlns:xlink="http://www.w3.org/1999/xlink">,</bold>
Tissue samples from growing and quiescent collateral arteries were disrupted in extraction buffer (0.1 M Tris-HCl, 0.01 M EDTA, 0.04 M DTT, 10% SDS, pH 8.0) using an ultrasonic device (Sonoplus G70, Bandelin, Berlin, Germany) with the following settings: five times 30 s, 40% power, 50% cycle. Proteins lysates were separated on a 4-12% Bis-Tris gel (Invitrogen, Karlsruhe, Germany). To deglycosylate protein samples, 50 mug of protein was denatured at 100degreesC for 10 min in 1x Denaturing buffer (NEB, Frankfurt, Germany), in a total volume of 12 mul. The denatured protein mixture was placed on ice, and 2 mul 10x G7 buffer, 2 mul 10% NP-40, and 2 mul PNGase F (500 U/mul, NEB, Frankfurt, Germany) were added. The reaction continued for 2 h at 37degreesC. Deglycosylated proteins were separated on a 4-12% Bis-Tris gel (Invitrogen, Karlsruhe, Germany).
###end p 16
###begin p 17
###xml 46 49 <span type="species:ncbi:10116">rat</span>
###xml 176 182 <span type="species:ncbi:9986">rabbit</span>
###xml 285 289 <span type="species:ncbi:9925">goat</span>
###xml 295 298 <span type="species:ncbi:10116">rat</span>
Osteoglycin was detected on the blots using a rat polyclonal antibody produced by Eurogentec (Double XP program, Koeln, Germany) after immunization with a peptide derived from rabbit osteoglycin (amino acids 79-84, VTPAPPKKENDEMPTC). The secondary antibody was a peroxidase-conjugated goat anti-rat IgG (Santa Cruz, Heidelberg, Germany). Immunoreactive bands were visualized with the ECL system (Amersham Biosciences, Freiburg, Germany). All experiments were repeated independently three times.
###end p 17
###begin title 18
In situ hybridization and immunohistochemistry
###end title 18
###begin p 19
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
The analyses of osteoglycin mRNA and protein in the growing collaterals by in situ hybridization and immunochemistry were done as described recently [21].
###end p 19
###begin p 20
###xml 348 350 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
Furthermore, when appropriate, in situ hybridization with osteoglycin RNA probes or immunoperoxidase staining with the protein was combined with immunofluorescence with vascular smooth muscle alpha-actin antibodies (Sigma, Munich, Germany; data not shown) or with the proliferation marker ki67 (Dako, Hamburg, Germany) in consecutive cryosections [21]. The omission of the first antibody served as negative control.
###end p 20
###begin p 21
###xml 342 349 <span type="species:ncbi:9986">rabbits</span>
Immunohistochemistry and photomicrography for osteoglycin were performed equally in all the sections, in order to minimize variability generated by the method. The intensity of osteoglycin immunostaining was qualitatively compared between sections, taken at comparable locations, from quadriceps muscles of six occluded and six sham operated rabbits.
###end p 21
###begin title 22
Cell culture
###end title 22
###begin p 23
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 430 431 424 425 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 28 34 <span type="species:ncbi:9986">rabbit</span>
###xml 605 610 <span type="species:ncbi:9606">human</span>
We used primary cultures of rabbit aortic SMCs, which were isolated as described previously for porcine aortic SMCs [22]. Cells were routinely cultured in medium 199 (PAA, Coelbe, Germany) with 20% FCS and splitted 1:4 upon confluence. For stimulation, cells between passages 4 and 6 were serum starved for 3 days. Stimulation was done with Oncostatin M (OsM, 10 ng/ml), FGF-2 (20 ng/ml), transforming growth factor-beta (TGF-beta1, 5 ng/ml), platelet derived growth factor-AB (PDGF-AB, 10 ng/ml), and granulocyte-macrophage colony-stimulating factor (GM-CSF, 10 ng/ml). All factors used were recombinant human (Cell Concepts, Umkirch, Germany).
###end p 23
###begin p 24
To test the influence of MCP-1 (10 ng/ml, Boehringer, Mannheim, Germany) on growth factor actions, all stimulations were repeated as co-stimulations with this chemokine. RNA was isolated from stimulated and co-stimulated cells after 24, 48, and 72 h, with peqGOLD RNApure (PEQLAB, Erlangen, Germany). All experiments were repeated three times.
###end p 24
###begin title 25
Statistics
###end title 25
###begin p 26
###xml 72 73 72 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Statistical comparisons were performed with ANOVA and Bonferroni tests. P values <0.05 were regarded as statistical significant.
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
###xml 36 42 <span type="species:ncbi:9986">rabbit</span>
Cloning and characterization of the rabbit osteoglycin cDNA
###end title 28
###begin p 29
###xml 219 225 219 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M37974</italic>
###xml 378 379 378 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 764 765 764 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 935 941 935 941 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1150 1160 1150 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">underlined</italic>
###xml 1235 1238 1235 1238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1293 1297 1293 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 1321 1326 1321 1326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 941 1326 941 1326 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Sequence of rabbit osteoglycin. The rabbit osteoglycin cDNA consisted of 2,493&#160;bp and contained an open reading frame coding for a protein of 298aa. The protein starts with a signal peptide of 19 amino acids (<italic>underlined</italic>). The three consensus sequences for N-linked glycosylation are printed in <italic>red</italic>. The leucine-rich repeats of the S-type are marked in <italic>blue</italic>, that of the T-type in <italic>green</italic></p>
###xml 941 1326 941 1326 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Sequence of rabbit osteoglycin. The rabbit osteoglycin cDNA consisted of 2,493&#160;bp and contained an open reading frame coding for a protein of 298aa. The protein starts with a signal peptide of 19 amino acids (<italic>underlined</italic>). The three consensus sequences for N-linked glycosylation are printed in <italic>red</italic>. The leucine-rich repeats of the S-type are marked in <italic>blue</italic>, that of the T-type in <italic>green</italic></p></caption>
###xml 1326 1326 1326 1326 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11010_2008_9935_Fig1_HTML" id="MO1"/>
###xml 935 1326 935 1326 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="30">Sequence of rabbit osteoglycin. The rabbit osteoglycin cDNA consisted of 2,493&#160;bp and contained an open reading frame coding for a protein of 298aa. The protein starts with a signal peptide of 19 amino acids (<italic>underlined</italic>). The three consensus sequences for N-linked glycosylation are printed in <italic>red</italic>. The leucine-rich repeats of the S-type are marked in <italic>blue</italic>, that of the T-type in <italic>green</italic></p></caption><graphic position="anchor" xlink:href="11010_2008_9935_Fig1_HTML" id="MO1"/></fig>
###xml 175 181 <span type="species:ncbi:9913">bovine</span>
###xml 320 326 <span type="species:ncbi:9986">rabbit</span>
###xml 345 351 <span type="species:ncbi:9913">bovine</span>
###xml 790 796 <span type="species:ncbi:9986">rabbit</span>
###xml 836 841 <span type="species:ncbi:9606">human</span>
###xml 843 849 <span type="species:ncbi:9913">bovine</span>
###xml 855 858 <span type="species:ncbi:10116">rat</span>
###xml 953 959 <span type="species:ncbi:9986">rabbit</span>
###xml 977 983 <span type="species:ncbi:9986">rabbit</span>
Using DDRT-PCR, we identified 191 differentially expressed genes, most of which were downregulated at 3d and 3 weeks. One of these genes showed a strong homology (77%) to the bovine osteoinductive factor (accession no. M37974). We cloned the full-length cDNA of 2.5 kb by 5' RACE and found that the gene represented the rabbit orthologue of the bovine osteoglycin/mimecan (Fig. 1). A single open reading frame of 896 bp coded for a protein of 298 amino acids. Conserved amino acid elements included an N-terminal signal peptide and three consensus sequences for N-linked glycosylation. Furthermore, the amino acid sequence showed seven leucine rich repeats; three of them represented the 21 amino acid S type and four of them the longer 26 amino acid T type (Fig. 1). The comparison of the rabbit osteoglycin amino acid sequence to the human, bovine, and rat ones showed an identity of 88%, 87%, and 83%, respectively (data not shown).Fig. 1Sequence of rabbit osteoglycin. The rabbit osteoglycin cDNA consisted of 2,493 bp and contained an open reading frame coding for a protein of 298aa. The protein starts with a signal peptide of 19 amino acids (underlined). The three consensus sequences for N-linked glycosylation are printed in red. The leucine-rich repeats of the S-type are marked in blue, that of the T-type in green
###end p 29
###begin p 30
###xml 209 219 209 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">underlined</italic>
###xml 294 297 294 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 352 356 352 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 380 385 380 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 12 18 <span type="species:ncbi:9986">rabbit</span>
###xml 36 42 <span type="species:ncbi:9986">rabbit</span>
Sequence of rabbit osteoglycin. The rabbit osteoglycin cDNA consisted of 2,493 bp and contained an open reading frame coding for a protein of 298aa. The protein starts with a signal peptide of 19 amino acids (underlined). The three consensus sequences for N-linked glycosylation are printed in red. The leucine-rich repeats of the S-type are marked in blue, that of the T-type in green
###end p 30
###begin title 31
Osteoglycin expression in collateral arteries
###end title 31
###begin p 32
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 264 265 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 279 280 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 479 480 479 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 607 613 607 613 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 703 704 703 704 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 704 714 704 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bar graphs</italic>
###xml 870 872 870 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#160;</italic>
###xml 911 913 911 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#160;</italic>
###xml 947 949 947 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#160;</italic>
###xml 955 956 955 956 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1018 1021 1018 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 1197 1203 1197 1203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 1247 1248 1245 1246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1266 1269 1264 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">con</italic>
###xml 613 1278 613 1276 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">Osteoglycin mRNA expression at various time points after occlusion of the femoral artery. <bold>A</bold><italic>Bar graphs</italic> representing Northern blot results on osteoglycin expression in growing collateral arteries from 3&#160;h to 3&#160;weeks after femoral artery ligation (for 3&#8211;24&#160;h: <italic>n&#160;</italic>=&#160;4 for each time point; for 3d to 3w: <italic>n&#160;</italic>=&#160;8 for each time point; control: <italic>n&#160;</italic>=&#160;8). <bold>B</bold> Representative Northern blot showing osteoglycin expression (<italic>top</italic>) in quiescent (con) and growing collateral arteries at days&#160;3, 7 as well as 3&#160;weeks after femoral artery occlusion. The blot was rehybridized with an 18S rRNA specific probe (<italic>bottom</italic>). Results are expressed as mean&#160;&#177;&#160;SEM (*&#160;<italic>P</italic>&#160;&lt;&#160;05 versus con; <italic>con</italic> control)</p>
###xml 613 1278 613 1276 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33">Osteoglycin mRNA expression at various time points after occlusion of the femoral artery. <bold>A</bold><italic>Bar graphs</italic> representing Northern blot results on osteoglycin expression in growing collateral arteries from 3&#160;h to 3&#160;weeks after femoral artery ligation (for 3&#8211;24&#160;h: <italic>n&#160;</italic>=&#160;4 for each time point; for 3d to 3w: <italic>n&#160;</italic>=&#160;8 for each time point; control: <italic>n&#160;</italic>=&#160;8). <bold>B</bold> Representative Northern blot showing osteoglycin expression (<italic>top</italic>) in quiescent (con) and growing collateral arteries at days&#160;3, 7 as well as 3&#160;weeks after femoral artery occlusion. The blot was rehybridized with an 18S rRNA specific probe (<italic>bottom</italic>). Results are expressed as mean&#160;&#177;&#160;SEM (*&#160;<italic>P</italic>&#160;&lt;&#160;05 versus con; <italic>con</italic> control)</p></caption>
###xml 1278 1278 1276 1276 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11010_2008_9935_Fig2_HTML" id="MO2"/>
###xml 607 1278 607 1276 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="33">Osteoglycin mRNA expression at various time points after occlusion of the femoral artery. <bold>A</bold><italic>Bar graphs</italic> representing Northern blot results on osteoglycin expression in growing collateral arteries from 3&#160;h to 3&#160;weeks after femoral artery ligation (for 3&#8211;24&#160;h: <italic>n&#160;</italic>=&#160;4 for each time point; for 3d to 3w: <italic>n&#160;</italic>=&#160;8 for each time point; control: <italic>n&#160;</italic>=&#160;8). <bold>B</bold> Representative Northern blot showing osteoglycin expression (<italic>top</italic>) in quiescent (con) and growing collateral arteries at days&#160;3, 7 as well as 3&#160;weeks after femoral artery occlusion. The blot was rehybridized with an 18S rRNA specific probe (<italic>bottom</italic>). Results are expressed as mean&#160;&#177;&#160;SEM (*&#160;<italic>P</italic>&#160;&lt;&#160;05 versus con; <italic>con</italic> control)</p></caption><graphic position="anchor" xlink:href="11010_2008_9935_Fig2_HTML" id="MO2"/></fig>
###xml 26 32 <span type="species:ncbi:9986">rabbit</span>
Northern blot analyses on rabbit collateral arteries showed a 3.2 kb mRNA which was downregulated at nearly all time points studied (Fig. 2). The mRNA level was decreased to 31% of the control value as early as 6 and 12 h after femoral artery ligation (all values P < 0.05, Fig. 2A). One day after surgery, osteoglycin production was still 52% of the control value, remaining at low levels during the entire first week of arteriogenesis (3 days, 43% and 7 days, 42%, of control; P < 0.05; Fig. 2B). After 3 weeks, osteoglycin expression started to return to control levels (86% of control; not significant).Fig. 2Osteoglycin mRNA expression at various time points after occlusion of the femoral artery. ABar graphs representing Northern blot results on osteoglycin expression in growing collateral arteries from 3 h to 3 weeks after femoral artery ligation (for 3-24 h: n = 4 for each time point; for 3d to 3w: n = 8 for each time point; control: n = 8). B Representative Northern blot showing osteoglycin expression (top) in quiescent (con) and growing collateral arteries at days 3, 7 as well as 3 weeks after femoral artery occlusion. The blot was rehybridized with an 18S rRNA specific probe (bottom). Results are expressed as mean +/- SEM (* P < 05 versus con; con control)
###end p 32
###begin p 33
###xml 90 91 90 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 91 101 91 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bar graphs</italic>
###xml 257 259 257 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#160;</italic>
###xml 298 300 298 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#160;</italic>
###xml 334 336 334 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#160;</italic>
###xml 342 343 342 343 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 405 408 405 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 584 590 584 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 634 635 632 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 653 656 651 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">con</italic>
Osteoglycin mRNA expression at various time points after occlusion of the femoral artery. ABar graphs representing Northern blot results on osteoglycin expression in growing collateral arteries from 3 h to 3 weeks after femoral artery ligation (for 3-24 h: n = 4 for each time point; for 3d to 3w: n = 8 for each time point; control: n = 8). B Representative Northern blot showing osteoglycin expression (top) in quiescent (con) and growing collateral arteries at days 3, 7 as well as 3 weeks after femoral artery occlusion. The blot was rehybridized with an 18S rRNA specific probe (bottom). Results are expressed as mean +/- SEM (* P < 05 versus con; con control)
###end p 33
###begin p 34
###xml 78 79 78 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 312 313 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 348 349 348 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 389 390 389 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 518 519 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 528 534 528 534 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 572 573 572 573 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 761 762 761 762 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 808 809 808 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 838 839 838 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 856 857 856 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 916 917 914 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 936 937 934 935 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1001 1002 999 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1132 1133 1130 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
###xml 1173 1176 1171 1174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">con</italic>
###xml 1186 1188 1184 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3d</italic>
###xml 1213 1215 1211 1213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">7d</italic>
###xml 1240 1242 1238 1240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3w</italic>
###xml 534 1267 534 1265 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">Western blot analyses of osteoglycin. <bold>A</bold> Representative Western blot showing the level of osteoglycin protein in growing collateral arteries at days 3, 7 and 3&#160;weeks after femoral artery occlusion as well as in control vessels. <bold>B</bold> Quantification of the Western blot analyses. <italic>n</italic>&#160;=&#160;7 for control and for d3, <italic>n</italic>&#160;=&#160;6 for d7, and <italic>n</italic>&#160;=&#160;5 for 3&#160;weeks. Results are expressed as mean&#160;&#177;&#160;SEM (*&#160;<italic>P</italic>&#160;&lt;&#160;05 versus con). <bold>C</bold> Protein preparations before (&#8722;) and after (+) deglycosylation (<italic>n</italic>&#160;=&#160;4 for each time point). Ponceau S staining was used in all Western blots to demonstrate equal loading of the protein samples. (<italic>M</italic> Cruz marker molecular weight standard, <italic>con</italic> control, <italic>3d</italic> 3&#160;days after occlusion, <italic>7d</italic> 7&#160;days after occlusion, <italic>3w</italic> 3&#160;weeks after occlusion)</p>
###xml 534 1267 534 1265 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">Western blot analyses of osteoglycin. <bold>A</bold> Representative Western blot showing the level of osteoglycin protein in growing collateral arteries at days 3, 7 and 3&#160;weeks after femoral artery occlusion as well as in control vessels. <bold>B</bold> Quantification of the Western blot analyses. <italic>n</italic>&#160;=&#160;7 for control and for d3, <italic>n</italic>&#160;=&#160;6 for d7, and <italic>n</italic>&#160;=&#160;5 for 3&#160;weeks. Results are expressed as mean&#160;&#177;&#160;SEM (*&#160;<italic>P</italic>&#160;&lt;&#160;05 versus con). <bold>C</bold> Protein preparations before (&#8722;) and after (+) deglycosylation (<italic>n</italic>&#160;=&#160;4 for each time point). Ponceau S staining was used in all Western blots to demonstrate equal loading of the protein samples. (<italic>M</italic> Cruz marker molecular weight standard, <italic>con</italic> control, <italic>3d</italic> 3&#160;days after occlusion, <italic>7d</italic> 7&#160;days after occlusion, <italic>3w</italic> 3&#160;weeks after occlusion)</p></caption>
###xml 1267 1267 1265 1265 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11010_2008_9935_Fig3_HTML" id="MO3"/>
###xml 528 1267 528 1265 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="35">Western blot analyses of osteoglycin. <bold>A</bold> Representative Western blot showing the level of osteoglycin protein in growing collateral arteries at days 3, 7 and 3&#160;weeks after femoral artery occlusion as well as in control vessels. <bold>B</bold> Quantification of the Western blot analyses. <italic>n</italic>&#160;=&#160;7 for control and for d3, <italic>n</italic>&#160;=&#160;6 for d7, and <italic>n</italic>&#160;=&#160;5 for 3&#160;weeks. Results are expressed as mean&#160;&#177;&#160;SEM (*&#160;<italic>P</italic>&#160;&lt;&#160;05 versus con). <bold>C</bold> Protein preparations before (&#8722;) and after (+) deglycosylation (<italic>n</italic>&#160;=&#160;4 for each time point). Ponceau S staining was used in all Western blots to demonstrate equal loading of the protein samples. (<italic>M</italic> Cruz marker molecular weight standard, <italic>con</italic> control, <italic>3d</italic> 3&#160;days after occlusion, <italic>7d</italic> 7&#160;days after occlusion, <italic>3w</italic> 3&#160;weeks after occlusion)</p></caption><graphic position="anchor" xlink:href="11010_2008_9935_Fig3_HTML" id="MO3"/></fig>
Western blot analyses revealed a double band of approximately 36-40 kDa (Fig. 3A), corresponding to glycosylated osteoglycin (see below). Changes in the expression level of the protein during arteriogenesis were comparable to those at the mRNA level. The protein content was reduced to 43% of the control value (P < 0.001) after 3 days and to 48% (P < 0.001) after 7 days of surgery (Fig. 3A, B). In contrast to RNA, the protein level was still low 3 weeks after occlusion of the femoral artery (40% of control value; P < 0.01).Fig. 3Western blot analyses of osteoglycin. A Representative Western blot showing the level of osteoglycin protein in growing collateral arteries at days 3, 7 and 3 weeks after femoral artery occlusion as well as in control vessels. B Quantification of the Western blot analyses. n = 7 for control and for d3, n = 6 for d7, and n = 5 for 3 weeks. Results are expressed as mean +/- SEM (* P < 05 versus con). C Protein preparations before (-) and after (+) deglycosylation (n = 4 for each time point). Ponceau S staining was used in all Western blots to demonstrate equal loading of the protein samples. (M Cruz marker molecular weight standard, con control, 3d 3 days after occlusion, 7d 7 days after occlusion, 3w 3 weeks after occlusion)
###end p 34
###begin p 35
###xml 38 39 38 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 227 228 227 228 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 274 275 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 304 305 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 322 323 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 382 383 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 402 403 400 401 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 467 468 465 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 598 599 596 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
###xml 639 642 637 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">con</italic>
###xml 652 654 650 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3d</italic>
###xml 679 681 677 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">7d</italic>
###xml 706 708 704 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3w</italic>
Western blot analyses of osteoglycin. A Representative Western blot showing the level of osteoglycin protein in growing collateral arteries at days 3, 7 and 3 weeks after femoral artery occlusion as well as in control vessels. B Quantification of the Western blot analyses. n = 7 for control and for d3, n = 6 for d7, and n = 5 for 3 weeks. Results are expressed as mean +/- SEM (* P < 05 versus con). C Protein preparations before (-) and after (+) deglycosylation (n = 4 for each time point). Ponceau S staining was used in all Western blots to demonstrate equal loading of the protein samples. (M Cruz marker molecular weight standard, con control, 3d 3 days after occlusion, 7d 7 days after occlusion, 3w 3 weeks after occlusion)
###end p 35
###begin p 36
###xml 212 213 212 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 410 411 410 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 500 501 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
Osteoglycin was initially described as a keratan sulfate proteoglycan. The core protein can be modified with oligosaccharides at three possible sites for N-glycosylation present in the osteoglycin sequence (Fig. 1). To test whether the detected signals of immunoreactive osteoglycin reflected the unmodified or the glycosylated protein in collateral arteries, the oligosaccharide side chains were removed with N-glycanase, resulting in a shift in the size of the protein of approximately 3 kDa (Fig. 3C), indicating that osteoglycin is expressed in collateral arteries as a glycoprotein without keratan sulfate side chains.
###end p 36
###begin title 37
Localization of osteoglycin mRNA and protein
###end title 37
###begin p 38
###xml 135 136 135 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 318 319 318 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 540 541 540 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 942 943 942 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 1074 1075 1074 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 1381 1382 1381 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 1388 1394 1388 1394 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 1428 1429 1428 1429 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 1431 1432 1431 1432 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1434 1435 1434 1435 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 1447 1448 1447 1448 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1450 1451 1450 1451 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 1453 1454 1453 1454 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 1493 1494 1493 1494 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 1543 1544 1543 1544 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 1546 1547 1546 1547 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1549 1550 1549 1550 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 1574 1575 1574 1575 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 1647 1648 1647 1648 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1650 1651 1650 1651 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 1736 1742 1736 1742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 1764 1774 1764 1774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 1777 1778 1777 1778 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1780 1781 1780 1781 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 1783 1784 1783 1784 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 1807 1808 1807 1808 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1857 1858 1857 1858 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 1949 1954 1949 1954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 2020 2036 2020 2036 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black arrowheads</italic>
###xml 2039 2040 2039 2040 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 2042 2043 2042 2043 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 2169 2175 2169 2175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 2179 2180 2179 2180 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 2220 2221 2220 2221 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 2247 2253 2247 2253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 2257 2258 2257 2258 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 2383 2399 2383 2399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black arrowheads</italic>
###xml 2403 2404 2403 2404 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 2409 2410 2409 2410 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 2488 2502 2488 2502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red arrowheads</italic>
###xml 1394 2503 1394 2503 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39">Localization of osteoglycin mRNA (<bold>A</bold>, <bold>C</bold>, <bold>D</bold>), protein (<bold>B</bold>, <bold>E</bold>, <bold>F</bold>), and the proliferation marker ki-67 (<bold>G</bold>) in collateral arteries and surrounding tissue. <bold>A</bold>, <bold>C</bold>, <bold>D</bold> In&#160;situ hybridization. <bold>A</bold> The hybridization with the sense probe was used as a negative control. <bold>C</bold>, <bold>D</bold> Positive signals for osteoglycin were detected in the SMCs of the collateral media (<italic>arrows</italic>) and in fibroblasts (<italic>arrowheads</italic>). <bold>B</bold>, <bold>E</bold>, <bold>F</bold> Immunohistochemistry. <bold>B</bold> Negative control for immunoperoxidase reaction. <bold>E</bold> Quiescent collateral arteries showed a thin media and continuous internal elastic lamina (<italic>arrow</italic>). Note the prominent staining for osteoglycin in the adventitia (<italic>black arrowheads</italic>). <bold>F</bold>, <bold>G</bold> (consecutive sections): After 7&#160;days of femoral artery occlusion growing collateral arteries show fragmented elastic lamina (<italic>arrows</italic> in <bold>F</bold>), prominent neointima formation (NI in <bold>F</bold>), and SMC proliferation (<italic>arrows</italic> in <bold>G</bold>; ki67 staining). Note the strong reduction of osteoglycin protein in the adventitia of growing collateral arteries (compare <italic>black arrowheads</italic> in <bold>E</bold> and <bold>F</bold>), whereas in the fascia of the muscle the signal intensity remains the same (<italic>red arrowheads</italic>)</p>
###xml 1394 2503 1394 2503 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39">Localization of osteoglycin mRNA (<bold>A</bold>, <bold>C</bold>, <bold>D</bold>), protein (<bold>B</bold>, <bold>E</bold>, <bold>F</bold>), and the proliferation marker ki-67 (<bold>G</bold>) in collateral arteries and surrounding tissue. <bold>A</bold>, <bold>C</bold>, <bold>D</bold> In&#160;situ hybridization. <bold>A</bold> The hybridization with the sense probe was used as a negative control. <bold>C</bold>, <bold>D</bold> Positive signals for osteoglycin were detected in the SMCs of the collateral media (<italic>arrows</italic>) and in fibroblasts (<italic>arrowheads</italic>). <bold>B</bold>, <bold>E</bold>, <bold>F</bold> Immunohistochemistry. <bold>B</bold> Negative control for immunoperoxidase reaction. <bold>E</bold> Quiescent collateral arteries showed a thin media and continuous internal elastic lamina (<italic>arrow</italic>). Note the prominent staining for osteoglycin in the adventitia (<italic>black arrowheads</italic>). <bold>F</bold>, <bold>G</bold> (consecutive sections): After 7&#160;days of femoral artery occlusion growing collateral arteries show fragmented elastic lamina (<italic>arrows</italic> in <bold>F</bold>), prominent neointima formation (NI in <bold>F</bold>), and SMC proliferation (<italic>arrows</italic> in <bold>G</bold>; ki67 staining). Note the strong reduction of osteoglycin protein in the adventitia of growing collateral arteries (compare <italic>black arrowheads</italic> in <bold>E</bold> and <bold>F</bold>), whereas in the fascia of the muscle the signal intensity remains the same (<italic>red arrowheads</italic>)</p></caption>
###xml 2503 2503 2503 2503 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11010_2008_9935_Fig4_HTML" id="MO4"/>
###xml 1388 2503 1388 2503 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="39">Localization of osteoglycin mRNA (<bold>A</bold>, <bold>C</bold>, <bold>D</bold>), protein (<bold>B</bold>, <bold>E</bold>, <bold>F</bold>), and the proliferation marker ki-67 (<bold>G</bold>) in collateral arteries and surrounding tissue. <bold>A</bold>, <bold>C</bold>, <bold>D</bold> In&#160;situ hybridization. <bold>A</bold> The hybridization with the sense probe was used as a negative control. <bold>C</bold>, <bold>D</bold> Positive signals for osteoglycin were detected in the SMCs of the collateral media (<italic>arrows</italic>) and in fibroblasts (<italic>arrowheads</italic>). <bold>B</bold>, <bold>E</bold>, <bold>F</bold> Immunohistochemistry. <bold>B</bold> Negative control for immunoperoxidase reaction. <bold>E</bold> Quiescent collateral arteries showed a thin media and continuous internal elastic lamina (<italic>arrow</italic>). Note the prominent staining for osteoglycin in the adventitia (<italic>black arrowheads</italic>). <bold>F</bold>, <bold>G</bold> (consecutive sections): After 7&#160;days of femoral artery occlusion growing collateral arteries show fragmented elastic lamina (<italic>arrows</italic> in <bold>F</bold>), prominent neointima formation (NI in <bold>F</bold>), and SMC proliferation (<italic>arrows</italic> in <bold>G</bold>; ki67 staining). Note the strong reduction of osteoglycin protein in the adventitia of growing collateral arteries (compare <italic>black arrowheads</italic> in <bold>E</bold> and <bold>F</bold>), whereas in the fascia of the muscle the signal intensity remains the same (<italic>red arrowheads</italic>)</p></caption><graphic position="anchor" xlink:href="11010_2008_9935_Fig4_HTML" id="MO4"/></fig>
The sites of osteoglycin production and accumulation in collateral arteries were investigated in detail by in situ hybridization (Fig. 4A, C, D) and immunohistochemistry (Fig. 4B, E, F), respectively. In collateral arteries, osteoglycin mRNA was mainly expressed by SMCs of the media and cells of the adventitia (Fig. 4C, D). In perivascular areas, signals were prominent in the fibroblasts of the fascia that envelops the skeletal muscles. Localization of osteoglycin protein was analyzed using the same antibody as for Western blot (Fig. 4E). The protein was accumulated in the ECM, with the strongest signals present in the adventitia of the arteries and the external fascia of the quadriceps muscles. Moderate signals were detected in the matrix surrounding individual muscle fibers. After 7 days of collateral artery growth, the amount of osteoglycin protein was clearly diminished in the adventitia of growing collateral arteries (Fig. 4F). These were distinguishable from neighboring quiescent arteries by the high percentage of proliferating SMCs in the media (Fig. 4G). Only growing collateral arteries from ligated animals showed a reduction of osteoglycin signals in the adventitia, whereas quiescent arteries from the same individuals, and from sham operated animals, as well as the muscle fascia of every specimen showed a constant intensity of staining (compare Fig. 4E, F).Fig. 4Localization of osteoglycin mRNA (A, C, D), protein (B, E, F), and the proliferation marker ki-67 (G) in collateral arteries and surrounding tissue. A, C, D In situ hybridization. A The hybridization with the sense probe was used as a negative control. C, D Positive signals for osteoglycin were detected in the SMCs of the collateral media (arrows) and in fibroblasts (arrowheads). B, E, F Immunohistochemistry. B Negative control for immunoperoxidase reaction. E Quiescent collateral arteries showed a thin media and continuous internal elastic lamina (arrow). Note the prominent staining for osteoglycin in the adventitia (black arrowheads). F, G (consecutive sections): After 7 days of femoral artery occlusion growing collateral arteries show fragmented elastic lamina (arrows in F), prominent neointima formation (NI in F), and SMC proliferation (arrows in G; ki67 staining). Note the strong reduction of osteoglycin protein in the adventitia of growing collateral arteries (compare black arrowheads in E and F), whereas in the fascia of the muscle the signal intensity remains the same (red arrowheads)
###end p 38
###begin p 39
###xml 34 35 34 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 37 38 37 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 40 41 40 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 53 54 53 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 56 57 56 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 59 60 59 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 99 100 99 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 149 150 149 150 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 152 153 152 153 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 155 156 155 156 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 180 181 180 181 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 253 254 253 254 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 256 257 256 257 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 342 348 342 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 370 380 370 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 383 384 383 384 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 386 387 386 387 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 389 390 389 390 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 413 414 413 414 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 463 464 463 464 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 555 560 555 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 626 642 626 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black arrowheads</italic>
###xml 645 646 645 646 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 648 649 648 649 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 775 781 775 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 785 786 785 786 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 826 827 826 827 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 853 859 853 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 863 864 863 864 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 989 1005 989 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black arrowheads</italic>
###xml 1009 1010 1009 1010 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 1015 1016 1015 1016 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 1094 1108 1094 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red arrowheads</italic>
Localization of osteoglycin mRNA (A, C, D), protein (B, E, F), and the proliferation marker ki-67 (G) in collateral arteries and surrounding tissue. A, C, D In situ hybridization. A The hybridization with the sense probe was used as a negative control. C, D Positive signals for osteoglycin were detected in the SMCs of the collateral media (arrows) and in fibroblasts (arrowheads). B, E, F Immunohistochemistry. B Negative control for immunoperoxidase reaction. E Quiescent collateral arteries showed a thin media and continuous internal elastic lamina (arrow). Note the prominent staining for osteoglycin in the adventitia (black arrowheads). F, G (consecutive sections): After 7 days of femoral artery occlusion growing collateral arteries show fragmented elastic lamina (arrows in F), prominent neointima formation (NI in F), and SMC proliferation (arrows in G; ki67 staining). Note the strong reduction of osteoglycin protein in the adventitia of growing collateral arteries (compare black arrowheads in E and F), whereas in the fascia of the muscle the signal intensity remains the same (red arrowheads)
###end p 39
###begin title 40
Factors influencing osteoglycin expression in vitro
###end title 40
###begin p 41
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 324 325 324 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 355 356 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 471 472 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 561 562 558 559 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 767 773 764 770 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;5</label>
###xml 837 847 834 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bar graphs</italic>
###xml 1144 1145 1139 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1165 1168 1160 1163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">con</italic>
###xml 1178 1181 1173 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OsM</italic>
###xml 773 1241 770 1236 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42">Stimulation of SMCs with distinct cytokines and growth factors. <italic>Bar graphs</italic> representing Northern blot results on osteoglycin expression in primary rabbit SMCs after 24, 48, and 72&#160;h of stimulation with distinct growth factors and cytokines. The factors and concentrations used are indicated in the &#8220;Material and Methods&#8221; section. Results are expressed as mean&#160;&#177;&#160;SEM (*&#160;<italic>P</italic>&#160;&lt;&#160;0.05 versus con; <italic>con</italic> control, <italic>OsM</italic> Oncostatin M). All experiments were performed in triplicate</p>
###xml 773 1241 770 1236 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42">Stimulation of SMCs with distinct cytokines and growth factors. <italic>Bar graphs</italic> representing Northern blot results on osteoglycin expression in primary rabbit SMCs after 24, 48, and 72&#160;h of stimulation with distinct growth factors and cytokines. The factors and concentrations used are indicated in the &#8220;Material and Methods&#8221; section. Results are expressed as mean&#160;&#177;&#160;SEM (*&#160;<italic>P</italic>&#160;&lt;&#160;0.05 versus con; <italic>con</italic> control, <italic>OsM</italic> Oncostatin M). All experiments were performed in triplicate</p></caption>
###xml 1241 1241 1236 1236 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11010_2008_9935_Fig5_HTML" id="MO5"/>
###xml 767 1241 764 1236 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig.&#160;5</label><caption><p textid="42">Stimulation of SMCs with distinct cytokines and growth factors. <italic>Bar graphs</italic> representing Northern blot results on osteoglycin expression in primary rabbit SMCs after 24, 48, and 72&#160;h of stimulation with distinct growth factors and cytokines. The factors and concentrations used are indicated in the &#8220;Material and Methods&#8221; section. Results are expressed as mean&#160;&#177;&#160;SEM (*&#160;<italic>P</italic>&#160;&lt;&#160;0.05 versus con; <italic>con</italic> control, <italic>OsM</italic> Oncostatin M). All experiments were performed in triplicate</p></caption><graphic position="anchor" xlink:href="11010_2008_9935_Fig5_HTML" id="MO5"/></fig>
###xml 8 14 <span type="species:ncbi:9986">rabbit</span>
###xml 920 926 <span type="species:ncbi:9986">rabbit</span>
Primary rabbit aortic SMCs were used to investigate the influence of growth factors on the expression of osteoglycin (Fig. 5). While most factors used showed no or only a negligible effect Oncostatin M led to a significant reduction of osteoglycin mRNA to 40% of the control value after 24 h of stimulation, 31% after 48 h (P < 0.05), and 27% after 72 h (P < 0.05). FGF-2 showed a comparable but biphasic effect, with a downregulation to 36% of control value after 24 h (P < 0.05), expression levels of 80% after 48 h, dropping again to 40% after 72 h. TGF-beta1 had only a short, limited effect after 48 h of stimulation, similar to PDGF-AB, with a downregulation to 60% and 63% of the control value, respectively. GM-CSF or MCP-1 alone showed no substantial effect.Fig. 5Stimulation of SMCs with distinct cytokines and growth factors. Bar graphs representing Northern blot results on osteoglycin expression in primary rabbit SMCs after 24, 48, and 72 h of stimulation with distinct growth factors and cytokines. The factors and concentrations used are indicated in the "Material and Methods" section. Results are expressed as mean +/- SEM (* P < 0.05 versus con; con control, OsM Oncostatin M). All experiments were performed in triplicate
###end p 41
###begin p 42
###xml 64 74 64 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bar graphs</italic>
###xml 371 372 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 392 395 390 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">con</italic>
###xml 405 408 403 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OsM</italic>
###xml 147 153 <span type="species:ncbi:9986">rabbit</span>
Stimulation of SMCs with distinct cytokines and growth factors. Bar graphs representing Northern blot results on osteoglycin expression in primary rabbit SMCs after 24, 48, and 72 h of stimulation with distinct growth factors and cytokines. The factors and concentrations used are indicated in the "Material and Methods" section. Results are expressed as mean +/- SEM (* P < 0.05 versus con; con control, OsM Oncostatin M). All experiments were performed in triplicate
###end p 42
###begin p 43
###xml 153 154 150 151 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 273 274 267 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 293 294 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 355 356 346 347 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
MCP-1 is a well-known stimulator of arteriogenesis when used either isolated or in combination with other factors like GM-CSF. Co-stimulation of TGF-beta1 with MCP-1 caused a deeper effect on osteoglycin downregulation (24 h: 89%, 48 h: 40%, 72 h: 29%) than single TGF-beta1 stimulation (Fig. 5). Co-stimulations using GM-CSF and MCP-1 or GM-CSF, TGF-beta1, and MCP-1 also showed prominent but non-significant reductions when compared to single stimulations.
###end p 43
###begin title 44
FGF-2 as a modulator of osteoglycin expression in vivo
###end title 44
###begin p 45
###xml 554 555 554 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 625 626 625 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 753 754 753 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 757 763 757 763 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;6</label>
###xml 827 828 827 828 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 901 902 901 902 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 977 978 977 978 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1109 1110 1109 1110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1165 1171 1165 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 1214 1215 1214 1215 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 1215 1225 1215 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bar graphs</italic>
###xml 1456 1458 1456 1458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#160;</italic>
###xml 763 1538 763 1536 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="46">Application of PAS. Postmortem angiograms of rabbit hind limbs. <bold>A</bold> After 1&#160;week of infusion of PAS without ligation of the femoral artery. <bold>B</bold> After 1&#160;week of femoral artery ligation with concomitant infusion of PAS. <bold>C</bold> After 1&#160;week of femoral artery ligation without infusion of PAS. Upon femoral artery ligation, only rabbits not treated with PAS (<bold>C</bold>) showed collateral arteries with corkscrew formation (<italic>arrows</italic>), a typical sign for growing collaterals. <bold>D</bold><italic>Bar graphs</italic> representing Northern blot results on osteoglycin expression after 1&#160;week of infusion of PAS in resting collateral arteries (con&#160;+&#160;PAS) and in growing collateral arteries 7&#160;days after ligation of the femoral artery (7d occ&#160;+&#160;PAS; <italic>n&#160;</italic>=&#160;4). Results are expressed as mean&#160;&#177;&#160;SEM. No statistical difference was found</p>
###xml 763 1538 763 1536 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="46">Application of PAS. Postmortem angiograms of rabbit hind limbs. <bold>A</bold> After 1&#160;week of infusion of PAS without ligation of the femoral artery. <bold>B</bold> After 1&#160;week of femoral artery ligation with concomitant infusion of PAS. <bold>C</bold> After 1&#160;week of femoral artery ligation without infusion of PAS. Upon femoral artery ligation, only rabbits not treated with PAS (<bold>C</bold>) showed collateral arteries with corkscrew formation (<italic>arrows</italic>), a typical sign for growing collaterals. <bold>D</bold><italic>Bar graphs</italic> representing Northern blot results on osteoglycin expression after 1&#160;week of infusion of PAS in resting collateral arteries (con&#160;+&#160;PAS) and in growing collateral arteries 7&#160;days after ligation of the femoral artery (7d occ&#160;+&#160;PAS; <italic>n&#160;</italic>=&#160;4). Results are expressed as mean&#160;&#177;&#160;SEM. No statistical difference was found</p></caption>
###xml 1538 1538 1536 1536 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11010_2008_9935_Fig6_HTML" id="MO6"/>
###xml 757 1538 757 1536 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig6"><label>Fig.&#160;6</label><caption><p textid="46">Application of PAS. Postmortem angiograms of rabbit hind limbs. <bold>A</bold> After 1&#160;week of infusion of PAS without ligation of the femoral artery. <bold>B</bold> After 1&#160;week of femoral artery ligation with concomitant infusion of PAS. <bold>C</bold> After 1&#160;week of femoral artery ligation without infusion of PAS. Upon femoral artery ligation, only rabbits not treated with PAS (<bold>C</bold>) showed collateral arteries with corkscrew formation (<italic>arrows</italic>), a typical sign for growing collaterals. <bold>D</bold><italic>Bar graphs</italic> representing Northern blot results on osteoglycin expression after 1&#160;week of infusion of PAS in resting collateral arteries (con&#160;+&#160;PAS) and in growing collateral arteries 7&#160;days after ligation of the femoral artery (7d occ&#160;+&#160;PAS; <italic>n&#160;</italic>=&#160;4). Results are expressed as mean&#160;&#177;&#160;SEM. No statistical difference was found</p></caption><graphic position="anchor" xlink:href="11010_2008_9935_Fig6_HTML" id="MO6"/></fig>
###xml 540 547 <span type="species:ncbi:9986">rabbits</span>
###xml 655 662 <span type="species:ncbi:9986">rabbits</span>
###xml 808 814 <span type="species:ncbi:9986">rabbit</span>
###xml 1079 1086 <span type="species:ncbi:9986">rabbits</span>
As shown above, FGF-2, a key factor for arteriogenesis, induced a pattern of osteoglycin downregulation in SMCs similar to the pattern observed in vivo. Thus, we decided to investigate whether FGF-2 plays a role in the regulation of osteoglycin expression in vivo. Surgical occlusion of the femoral artery was accompanied with continuous systemic infusion of the FGF-2 inhibitor PAS during 7 days. Postmortem angiograms of PAS treated animals showed a strong reduction in collateral growth after femoral ligation when compared to untreated rabbits (Fig. 6A) who had big collateral arteries with a corkscrew-like course (Fig. 6C). In contrast, PAS treated rabbits showed small collateral arteries after femoral surgery, with no corkscrew formation (Fig. 6B).Fig. 6Application of PAS. Postmortem angiograms of rabbit hind limbs. A After 1 week of infusion of PAS without ligation of the femoral artery. B After 1 week of femoral artery ligation with concomitant infusion of PAS. C After 1 week of femoral artery ligation without infusion of PAS. Upon femoral artery ligation, only rabbits not treated with PAS (C) showed collateral arteries with corkscrew formation (arrows), a typical sign for growing collaterals. DBar graphs representing Northern blot results on osteoglycin expression after 1 week of infusion of PAS in resting collateral arteries (con + PAS) and in growing collateral arteries 7 days after ligation of the femoral artery (7d occ + PAS; n = 4). Results are expressed as mean +/- SEM. No statistical difference was found
###end p 45
###begin p 46
###xml 64 65 64 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 138 139 138 139 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 214 215 214 215 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 346 347 346 347 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 402 408 402 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 451 452 451 452 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 452 462 452 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bar graphs</italic>
###xml 693 695 693 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#160;</italic>
###xml 45 51 <span type="species:ncbi:9986">rabbit</span>
###xml 316 323 <span type="species:ncbi:9986">rabbits</span>
Application of PAS. Postmortem angiograms of rabbit hind limbs. A After 1 week of infusion of PAS without ligation of the femoral artery. B After 1 week of femoral artery ligation with concomitant infusion of PAS. C After 1 week of femoral artery ligation without infusion of PAS. Upon femoral artery ligation, only rabbits not treated with PAS (C) showed collateral arteries with corkscrew formation (arrows), a typical sign for growing collaterals. DBar graphs representing Northern blot results on osteoglycin expression after 1 week of infusion of PAS in resting collateral arteries (con + PAS) and in growing collateral arteries 7 days after ligation of the femoral artery (7d occ + PAS; n = 4). Results are expressed as mean +/- SEM. No statistical difference was found
###end p 46
###begin p 47
###xml 39 40 39 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 168 169 168 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 25 32 <span type="species:ncbi:9986">rabbits</span>
In contrast to untreated rabbits (Fig. 2), PAS treated specimens had no significant change of osteoglycin mRNA expression after 7 days of femoral artery ligation (Fig. 6D). Thus, PAS treatment abolished osteoglycin downregulation in collateral arteries induced by femoral ligation.
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 18 24 <span type="species:ncbi:9986">rabbit</span>
###xml 268 274 <span type="species:ncbi:9986">rabbit</span>
###xml 348 351 <span type="species:ncbi:10116">rat</span>
Our study defines rabbit osteoglycin, a protein of 298 amino acids and a prototype member of the family of small leucine-rich proteins (SLRP; for an overview see [14]) as a critical component of arteriogenesis. Northern blot results showed a single band of 3.2 kb for rabbit osteoglycin mRNA, which is in agreement with the published mRNA size for rat [23], therefore excluding differential splicing or alternative polyadenylation. The mRNA is translated in a glycosylated protein without keratan sulfate side chains of 36-40 kDa fitting with the theoretical mass (including the signal peptide) of 34 kDa [23].
###end p 49
###begin p 50
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 74 81 <span type="species:ncbi:9986">rabbits</span>
The comparative study of osteoglycin expression in collateral arteries of rabbits subjected to femoral artery occlusion indicated a clear downregulation during the entire period under investigation. Localization of osteoglycin mRNA and protein in skeletal muscles and vessels corresponded to that shown in previous studies [21]. One week after induction of arteriogenesis, osteoglycin protein was clearly diminished in the adventitia of growing collateral arteries, whereas the surrounding muscle fascia and quiescent vessels were unaffected. These data also illustrate the specificity of osteoglycin function in the process, as changes in the amount of the protein were restricted to growing collateral arteries, whereas osteoglycin amount in the skeletal muscle matrix did not change.
###end p 50
###begin p 51
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 230 236 <span type="species:ncbi:9986">rabbit</span>
Our results strongly support previous reports showing that osteoglycin expression is linked to SMC proliferation [23] because osteoglycin downregulation during arteriogenesis coincides with the proliferation phase of SMCs. In the rabbit hind limb model, proliferation starts 24 h after femoral artery occlusion, peaks between days 2 and 3, and gradually decreases until day 21 [24]. Moreover, downregulation starts even before mitosis is detected (6 and 12 h after surgery), suggesting that osteoglycin may be involved in SMC activation.
###end p 51
###begin p 52
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 304 310 <span type="species:ncbi:9913">bovine</span>
###xml 332 337 <span type="species:ncbi:9606">human</span>
We found evidence that application of FGF-2, a potent mitogen for SMCs and fibroblasts and a critical element in arteriogenesis [17], to SMCs in vitro closely mimicked the downregulation of osteoglycin observed during the first 3 days of arteriogenesis in vivo, similar to the one previously observed in bovine keratocytes [25] and human SMCs [23].
###end p 52
###begin p 53
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 961 963 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 965 967 965 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
In addition, infusion of PAS, a nontoxic sulfonic acid polymer described to block the action of FGF-2 via complex formation [26] and strongly interfering with arteriogenesis in vivo [17], completely inhibited the downregulation of osteoglycin. This demonstrates that FGF-2 is either directly or indirectly involved in regulating the expression of osteoglycin during the process of arteriogenesis in vivo, probably via the high-affinity receptor FGFR-1 which is expressed by SMCs of the collateral wall, whereas FGF-2 is mostly secreted by recruited macrophages [17]. Macrophage invasion and activation in the adventitia of collateral arteries by secreted cytokines like MCP-1 are critical events during arteriogenesis [27-29]. Interestingly, in our SMC cultures, MCP-1 co-stimulation enhanced the capacity of most factors tested to downregulate osteoglycin. Furthermore, Oncostatin M, another macrophage-secreted cytokine with a known mitogenic effect on SMCs [30, 31], induced a significant downregulation of osteoglycin at every time point studied. These data indicate that factors other than FGF-2 may influence osteoglycin expression during collateral growth and support the hypothesis that osteoglycin downregulation is a necessary mechanism for arteriogenesis progression.
###end p 53
###begin p 54
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 514 516 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 664 665 664 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 306 310 <span type="species:ncbi:10090">mice</span>
###xml 526 532 <span type="species:ncbi:9986">rabbit</span>
###xml 923 928 <span type="species:ncbi:10090">mouse</span>
The results of the present study point to a function of osteoglycin as a negative regulator of the mitotic activity in the wall of collateral arteries. However, the main function of osteoglycin as with other SLRPs may be the regulation of collagen fibrillogenesis in the ECM [14, 32]. Osteoglycin knockout mice show reduced tensile strength of the skin, caused by alterations in the diameters of collagen fibrils, thereby supporting a role for this proteoglycan in determining elasticity and tensile strength [21, 32]. During rabbit peripheral arteriogenesis, collateral artery remodeling leads to a final increase in size of 10-fold the original vessel diameter [7]. It is reasonable to propose that osteoglycin downregulation may influence the structure of the collagen matrix during the remodeling phase of arteriogenesis, allowing the structural dilatation of collateral arteries. New studies with osteoglycin knockout mouse models may help in understanding how this glycoprotein influences the mechanical properties of the vascular wall during vascular disease and adaptative growth.
###end p 54
###begin p 55
###xml 177 179 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
Finally, studies have shown that osteoglycin binds bone morphogenetic proteins (BMPs), members of the TGF-beta superfamily, thereby regulating their bioavailability and action [33]. Additional studies are required to address the possible involvement of BMPs in arteriogenesis and their regulation by osteoglycin.
###end p 55
###begin title 56
Acknowledgment
###end title 56
###begin p 57
We thank Prof. Dr. Dr. Thomas Braun for his support and the allowance to finish this work in his department. The authors appreciate the technical assistance of Marianne Granz, Kerstin Richter, and Claudia Ullmann and the expertise of Frank Voss and Gerd Stammler in performing statistical analysis.
###end p 57
###begin title 58
References
###end title 58
###begin article-title 59
Collateral circulation of the heart
###end article-title 59
###begin article-title 60
The range of adaptation by collateral vessels after femoral artery occlusion
###end article-title 60
###begin article-title 61
Receptor-independent role of the urokinase-type plasminogen activator during arteriogenesis
###end article-title 61
###begin article-title 62
Angiogenesis but not collateral growth is associated with ischemia after femoral artery occlusion
###end article-title 62
###begin article-title 63
###xml 65 71 <span type="species:ncbi:9986">rabbit</span>
Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb
###end article-title 63
###begin article-title 64
###xml 72 78 <span type="species:ncbi:9986">rabbit</span>
Time course of arteriogenesis following femoral artery occlusion in the rabbit
###end article-title 64
###begin article-title 65
Basic fibroblast growth factor enhances myocardial collateral flow in a canine model
###end article-title 65
###begin article-title 66
###xml 86 90 <span type="species:ncbi:7962">carp</span>
Arteriogenesis is associated with an induction of the cardiac ankyrin repeat protein (carp)
###end article-title 66
###begin article-title 67
Osteoglycin: a potential new target for the promotion of arteriogenesis?
###end article-title 67
###begin article-title 68
###xml 73 79 <span type="species:ncbi:9913">bovine</span>
Purification and characterization of a unique osteoinductive factor from bovine bone
###end article-title 68
###begin article-title 69
Mimecan, the 25-kDa corneal keratan sulfate proteoglycan, is a product of the gene producing osteoglycin
###end article-title 69
###begin article-title 70
Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo
###end article-title 70
###begin article-title 71
The family of small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth
###end article-title 71
###begin article-title 72
Differential expression of the extracellular matrix (ECM) components mimecan and elastin during arteriogenesis
###end article-title 72
###begin article-title 73
Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion
###end article-title 73
###begin article-title 74
Involvement of the fibroblast growth factor system in adaptive and chemokine-induced arteriogenesis
###end article-title 74
###begin article-title 75
Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
###end article-title 75
###begin article-title 76
Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction
###end article-title 76
###begin article-title 77
###xml 43 49 <span type="species:ncbi:9986">rabbit</span>
Osteoglycin expression and localization in rabbit tissues and atherosclerotic plaques
###end article-title 77
###begin article-title 78
Porcine aortic endothelial cells show little effects on smooth muscle cells but are potent stimulators of cardiomyocyte growth
###end article-title 78
###begin article-title 79
Identification of osteoglycin as a component of the vascular matrix. Differential expression during neointima formation and in atherosclerotic plaques
###end article-title 79
###begin article-title 80
###xml 42 48 <span type="species:ncbi:9986">rabbit</span>
Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis)
###end article-title 80
###begin article-title 81
Fibroblast growth factor-2 promotes keratan sulfate proteoglycan expression by keratocytes in vitro
###end article-title 81
###begin article-title 82
The sulfonic acid polymers PAMPS [poly(2-acrylamido-2-methyl-1-propanesulfonoc acid)] and related analogons are highly potent inhibitors of angiogenesis
###end article-title 82
###begin article-title 83
###xml 111 115 <span type="species:ncbi:10090">mice</span>
Arteriogenesis depends on circulating monocytes and macrophage accumulation and is severely depressed in op/op mice
###end article-title 83
###begin article-title 84
Reversibly injured, post-ischemic canine myocardium retains normal contractile reserve
###end article-title 84
###begin article-title 85
Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1
###end article-title 85
###begin article-title 86
###xml 30 36 <span type="species:ncbi:9986">rabbit</span>
Oncostatin M is a mitogen for rabbit vascular smooth muscle cells
###end article-title 86
###begin article-title 87
Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6
###end article-title 87
###begin article-title 88
###xml 30 34 <span type="species:ncbi:10090">mice</span>
Mimecan/osteoglycin-deficient mice have collagen fibril abnormalities
###end article-title 88
###begin article-title 89
###xml 59 63 <span type="species:ncbi:10090">mice</span>
Differentially expressed genes in the lens of mimecan-null mice
###end article-title 89
###begin p 90
###xml 115 123 115 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AF487889</italic>
The nucleotide sequence reported in this article has been submitted to the GenBank Data Bank with accession number AF487889.
###end p 90

